ACTA1 and chronic kidney disease: AMCZ markedly lowered the elevated levels of p-JNK, FN, Col-IV, α-SMA, IL-1β, and TNF-α in CKD rats, suggesting AMCZ attenuated renal fibrosis and inflammation through the modulation of SIRT1/JNK signaling pathway.